01—Abstract
Summary
Summary of the 8-K filed September 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) filed this Form 8-K on September 3, 2024 under Item 7.01 (Regulation FD Disclosure) to announce that members of its executive management team will take part in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024, at 3:10 p.m.
ET. The filing contains no financial results, guidance, or material transactions. Accompanying the filing is Exhibit 99.1, a press release dated September 3, 2024, which announces the conference appearance and describes Labcorp as a global provider of laboratory services with more than 67,000 employees serving clients in approximately 100 countries.
The press release also states that the company supported 84%a of new drugs and therapeutic products approved by the FDA in 2023 and performed more than 600 million tests for patients worldwide. For investors, this is a routine investor-relations disclosure. It signals management's availability to discuss the company with investors at a healthcare conference but does not itself disclose new operating or financial information.
02—Key points
Key Highlights
- Filed under Item 7.01 (Regulation FD Disclosure) on September 3, 2024, announcing executive management participation in a conference.
- Executive management team scheduled to present at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024, at 3:10 p.m. ET.
- Exhibit 99.1 is a press release dated September 3, 2024, announcing the conference appearance.
- The press release states Labcorp has more than 67,000 employees and serves clients in approximately 100 countries.
- The company states it supported 84% of new drugs and therapeutic products approved by the FDA in 2023.
- The company states it performed more than 600 million tests for patients worldwide.
- The filing reports no financial results, guidance, or material agreements.
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing discloses under Item 7.01 (Regulation FD Disclosure) that Labcorp's executive management team will present at the Baird 2024 Global Healthcare Conference on September 10, 2024, at 3:10 p.m. ET.
Does this filing contain financial results or guidance?
No. The filing is limited to announcing the conference presentation and does not include earnings results, financial guidance, or other financial metrics.
When and where will Labcorp's executive management present?
Labcorp's executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024, at 3:10 p.m. ET.
What exhibits accompany the filing?
Exhibit 99.1 is a press release dated September 3, 2024, announcing the conference participation, and Exhibit 104 is the cover page Interactive Data File embedded within the Inline XBRL document.
04—Continue